When did Curatis Holding AG announce the Neupharma agreement, and what market does it cover?

Curatis Holding AG announced the agreement on 11 March 2026, and it covers the development and commercialisation of corticorelin for PTBE in Japan. The agreement stipulates that corticorelin is planned to be introduced initially for children and adolescents in Japan.

What payments will Curatis Holding AG receive under the Neupharma agreement?

Curatis Holding AG will receive upfront and milestone payments for regulatory and commercial targets totalling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The payments are linked to the achievement of the stated targets and future sales.

Who will finance and conduct the Japanese clinical trial for Curatis Holding AG's corticorelin programme?

Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval there. The agreement gives Neupharma exclusive development and commercialisation rights for corticorelin in Japan.

What are the next clinical development milestones for Curatis Holding AG's corticorelin programme in Japan?

A meeting with Japan's drug regulatory authority, PMDA, to discuss the registration-enabling study is planned for summer 2026, and the clinical study is expected to start in 2027. The source also says preparatory work for the pivotal Phase 3 study for approval in the US and Europe, together with global partnering activities, is proceeding as planned.

What condition is Curatis Holding AG developing corticorelin to treat?

Curatis Holding AG is developing corticorelin to treat peritumoral brain edema (PTBE), a tumour-associated condition for which the source says no approved targeted therapies currently exist. PTBE involves the accumulation of extracellular fluid around a brain tumour and can cause headaches, vomiting and neurological dysfunction.

How does Curatis Holding AG describe the current treatment and risks associated with peritumoral brain edema?

The source says the standard-of-care treatment for PTBE is corticosteroids, which frequently have serious side effects including severe myopathy, impaired glucose metabolism, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. It also says corticosteroids can counteract certain cancer therapies, including chemotherapy or emerging immunotherapies that rely on adequate T-cell functionality.

What evidence does Curatis Holding AG cite for corticorelin?

Curatis Holding AG says corticorelin demonstrated preclinically, in vivo, the ability to positively impact the blood-brain barrier after disruption caused by an underlying malignant tumour. In two clinical studies in patients with PTBE, the treatment demonstrated the potential to substantially reduce, or in some cases completely replace, steroid use.

What is the estimated patient population and market potential for Curatis Holding AG's corticorelin treatment?

The available patient population eligible for corticorelin treatment associated with PTBE is estimated at 60,000 in Japan and 500,000 worldwide. The announcement says global market potential is forecasted to exceed USD 1 billion annually, while also noting that corticorelin is an investigational drug not approved for therapeutic use in the United States or outside the United States.

What does Curatis Holding AG do and how does its business operate?

Curatis Holding AG is a publicly listed company focused on the late-stage development and commercialisation of drugs for rare diseases and specialty care. The company says it has a sales portfolio of more than 40 products and a pipeline of orphan and specialty drugs.

Where are Curatis Holding AG's shares listed and which ticker symbols does it use?

Curatis Holding AG is identified in the announcement as listed on SIX under the ticker symbol CURN and as publicly listed under CURN.SW. The source does not identify any other listing venue or ticker symbol.

What regulatory status does Curatis Holding AG's corticorelin have?

Corticorelin is an investigational drug and is not approved for therapeutic use in the United States or outside the United States. The Japanese programme is intended to support a filing for approval in Japan through the planned pivotal clinical trial.

Home
News Intelligence
Curatis Holding AG
Curatis and Neupharma announce Japan licensing agreement for corticorelin

Back to all Curatis Holding AG press releases

Curatis Holding AG

SIX:CURN

Curatis and Neupharma announce Japan licensing agreement for corticorelin

Published Wednesday, 11 March 2026, 06:00 AM

Get alerts

Plain English summaries when Curatis Holding AG announces news.

At a glance

Company: Curatis Holding AG
Listings: SIX:CURN
Announcement type: Corporate update
Published: Wednesday, 11 March 2026, 06:00 AM
Source announcement: eqs-news.com

Key figures
Measure	Figure
Upfront and milestone payments	up to CHF 83.5 million
Royalties on future sales in Japan	up to 20%

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Curatis Holding AG (SIX: CURN; CURN.SW) and Neupharma announce an exclusive license and development agreement for corticorelin in Japan.

Neupharma receives exclusive Japanese rights to develop and commercialize corticorelin for peritumoral brain edema (PTBE), a tumor-associated condition without approved targeted therapies.
Curatis will receive upfront and milestone payments of up to CHF 83.5 million, tied to regulatory and commercial targets.
Curatis will receive royalties on future sales in Japan of up to 20%.
Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval.
Corticorelin is planned initially for children and adolescents; a PMDA meeting is planned for summer 2026, with the study expected in 2027.

Curatis says preparatory work for a pivotal Phase 3 study for approval in the US and Europe, plus global partnering activities, are proceeding as planned. Corticorelin is investigational and not approved in the United States or outside the United States.

Investor FAQs

Curatis Holding AG and Neupharma Co., Ltd. announced an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Neupharma will receive exclusive rights to develop and commercialise the treatment for peritumoral brain edema (PTBE) in Japan.

Source announcement

Company: Curatis Holding AG
Title: Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan
Published: Wednesday, 11 March 2026, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…